PE Rabbit anti-Mouse CD152/CTLA-4 Monoclonal Antibody for Flow Cytometry - P09793

Core Product Specifications and Parameters

Biological Background: CTLA-4 Function and Localization

• CTLA-4 (Cytotoxic T-lymphocyte protein 4) is an inhibitory receptor that acts as a major negative regulator of T-cell responses.
• It functions as a decoy receptor with a considerably higher affinity for the B7 ligands CD80 and CD86 compared to the costimulatory receptor CD28.
• CTLA-4 is localized at the cell membrane, participating in immune synapse modulation.
• The protein is widely expressed, with highest levels in lymphoid tissues, underpinning its role in adaptive immunity.
• Structurally, CTLA-4 is a glycoprotein containing an immunoglobulin domain, a single transmembrane helix, a signal peptide, and intramolecular disulfide bonds; its activity is modulated by phosphorylation.
• As a member of the immunoglobulin superfamily, CTLA-4 is a critical immune checkpoint molecule.

Experimental Guidance and Technical Tips

• The immunogen (residues 36–161) covers the extracellular ligand-binding domain, suggesting that the antibody may recognize the native conformation of CTLA-4 on live cells for flow cytometry applications.
• For flow cytometry, titrate the antibody to determine the optimal staining concentration and include an appropriate isotype control to assess non-specific binding.
• As CTLA-4 is predominantly expressed in lymphoid tissues, consider using mouse splenocytes or lymph node cells as positive control samples.
• Protect the PE conjugate from prolonged light exposure and avoid repeated freeze-thaw cycles to maintain fluorophore stability and antibody activity.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio offers diagnostic manufacturers and research laboratories a comprehensive, one-stop platform for procuring IVD raw materials, including validated monoclonal antibodies such as this anti-CTLA-4 clone. Our supply capabilities extend to optimized antibody pairs, bulk ancillary reagents, and sourcing of rare targets, ensuring a seamless transition from early-stage development to clinical applications in immune checkpoint and T-cell biology.